Literature DB >> 16118454

Approaches to evaluation of fibrogenic pathways in surgical lung biopsy specimens.

Cory M Hogaboam1, Kristin J Carpenter, Holly Evanoff, Steven L Kunkel.   

Abstract

Idiopathic interstitial pneumonias (IIPs) are a heterogeneous group of pulmonary fibrotic disorders consisting of several clinicopathologic entities with differing histopathologic patterns, clinical course, response to therapy, and prognosis. It is now recognized that accurate diagnosis is required in IIP, particularly in distinguishing various clinicopathologic entities of this disease from usual interstitial pneumonia, the most common histological pattern in IIP. Although no longer considered the "gold standard" for diagnosis, surgical lung biopsies (SLBs) have provided clinicians and researchers with important clues as to the identity of soluble mediators that may account for the subtype differences in IIP. Given that the expression of chemokine ligands and chemokine receptors appear to be markedly altered during the development of pulmonary fibrosis in IIP , we have focused on the characterization of these mediators in IIP and non-IIP SLBs and in primary human fibroblast lines grown from these biopsies. Herein, we describe laboratory techniques routinely employed to detect these important profibrotic factors and their corresponding receptors in SLBs and in primary human fibroblast lines.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16118454     DOI: 10.1385/1-59259-940-0:209

Source DB:  PubMed          Journal:  Methods Mol Med        ISSN: 1543-1894


  8 in total

1.  Loss of CDKN2B Promotes Fibrosis via Increased Fibroblast Differentiation Rather Than Proliferation.

Authors:  Anne M Scruggs; Hailey B Koh; Priya Tripathi; Nicholas J Leeper; Eric S White; Steven K Huang
Journal:  Am J Respir Cell Mol Biol       Date:  2018-08       Impact factor: 6.914

2.  Recognition of Candida albicans by gingival fibroblasts: The role of TLR2, TLR4/CD14, and MyD88.

Authors:  Claudia Ramos Pinheiro; Ana Lúcia Coelho; Carine Ervolino de Oliveira; Thaís Helena Gasparoto; Gustavo Pompermaier Garlet; João Santana Silva; Carlos Ferreira Santos; Karen Angélica Cavassani; Cory M Hogaboam; Ana Paula Campanelli
Journal:  Cytokine       Date:  2017-11-09       Impact factor: 3.861

3.  Variable prostaglandin E2 resistance in fibroblasts from patients with usual interstitial pneumonia.

Authors:  Steven K Huang; Scott H Wettlaufer; Cory M Hogaboam; Kevin R Flaherty; Fernando J Martinez; Jeffrey L Myers; Thomas V Colby; William D Travis; Galen B Toews; Marc Peters-Golden
Journal:  Am J Respir Crit Care Med       Date:  2007-10-04       Impact factor: 21.405

4.  Lung fibroblasts from patients with idiopathic pulmonary fibrosis exhibit genome-wide differences in DNA methylation compared to fibroblasts from nonfibrotic lung.

Authors:  Steven K Huang; Anne M Scruggs; Richard C McEachin; Eric S White; Marc Peters-Golden
Journal:  PLoS One       Date:  2014-09-12       Impact factor: 3.240

5.  TLR9 is expressed in idiopathic interstitial pneumonia and its activation promotes in vitro myofibroblast differentiation.

Authors:  A Meneghin; E S Choi; H L Evanoff; S L Kunkel; F J Martinez; K R Flaherty; G B Toews; C M Hogaboam
Journal:  Histochem Cell Biol       Date:  2008-07-17       Impact factor: 4.304

6.  Prostaglandin E(2) induces fibroblast apoptosis by modulating multiple survival pathways.

Authors:  Steven K Huang; Eric S White; Scott H Wettlaufer; Heather Grifka; Cory M Hogaboam; Victor J Thannickal; Jeffrey C Horowitz; Marc Peters-Golden
Journal:  FASEB J       Date:  2009-08-11       Impact factor: 5.191

7.  Targeting MAP3K19 prevents human lung myofibroblast activation both in vitro and in a humanized SCID model of idiopathic pulmonary fibrosis.

Authors:  Isabelle C Jones; Milena S Espindola; Rohan Narayanan; Ana L Coelho; David M Habiel; Stefen A Boehme; Tai Wei Ly; Kevin B Bacon; Cory M Hogaboam
Journal:  Sci Rep       Date:  2019-12-24       Impact factor: 4.379

8.  Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease.

Authors:  Ruoqi Peng; Sriram Sridhar; Gaurav Tyagi; Jonathan E Phillips; Rosario Garrido; Paul Harris; Lisa Burns; Lorena Renteria; John Woods; Leena Chen; John Allard; Palanikumar Ravindran; Hans Bitter; Zhenmin Liang; Cory M Hogaboam; Chris Kitson; David C Budd; Jay S Fine; Carla M T Bauer; Christopher S Stevenson
Journal:  PLoS One       Date:  2013-04-02       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.